microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2020-1-6-13microbe-1279Research ArticleСтатьиЭпидемиологические особенности новой коронавирусной инфекции(COVID-19). Сообщение 1: Модели реализации профилактических и противоэпидемических мероприятийEpidemiological Features of New Coronavirus Infection (COVID-19). Communication 1: Modes of Implementation of Preventive and Anti-Epidemic MeasuresКутыревВ. В.KutyrevV. V.rusrapi@microbe.ruПоповаА. Ю.PopovaA. Yu.СмоленскийВ. Ю.SmolenskyV. Yu.ЕжловаЕ. Б.EzhlovaE. B.ДеминаЮ. В.DeminaYu. V.СафроновВ. А.SafronovV. A.rusrapi@microbe.ruКарнауховИ. Г.KarnaukhovI. G.

Карнаухов Игорь Геннадьевич

Igor G. Karnaukhov

rusrapi@microbe.ruИвановаА. В.IvanovaA V.rusrapi@microbe.ruЩербаковаС. А.ShcherbakovaS. A.rusrapi@microbe.ruФКУЗ «Российский научно-исследовательский противочумный институт «Микроб»РоссияRussian Research Anti-Plague Institute “Microbe”Russian FederationФедеральная служба по надзору в сфере защиты прав потребителей и благополучия человека; Российская медицинская академия непрерывного профессионального образованияРоссияFederal Service for Surveillance in the Sphere of Consumers Rights Protection and Human Welfare; Russian Medical Academy of Continuing Professional EducationRussian FederationФедеральная служба по надзору в сфере защиты прав потребителей и благополучия человекаРоссияFederal Service for Surveillance in the Sphere of Consumers Rights Protection and Human WelfareRussian Federation20202004202001613Copyright © Кутырев В.В., Попова А.Ю., Смоленский В.Ю., Ежлова Е.Б., Демина Ю.В., Сафронов В.А., Карнаухов И.Г., Иванова А.В., Щербакова С.А., 20202020Кутырев В.В., Попова А.Ю., Смоленский В.Ю., Ежлова Е.Б., Демина Ю.В., Сафронов В.А., Карнаухов И.Г., Иванова А.В., Щербакова С.А.Kutyrev V.V., Popova A.Y., Smolensky V.Y., Ezhlova E.B., Demina Y.V., Safronov V.A., Karnaukhov I.G., Ivanova A.V., Shcherbakova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/1279

В статье приведены сведения об эпидемиологической обстановке в мире по COVID-19. Дана оценка основных эпидемиологических параметров (базовый репродуктивный показатель, летальность, инкубационный период и серийный интервал). Показана доля тяжелых случаев в разных возрастных группах и общая структура заболеваемости по тяжести клинического течения. Приведена типизация моделей реагирования в странах мира в зависимости от применяемого комплекса мероприятий на различных стадиях эпидемического процесса. Рассмотрены основные мероприятия по реагированию на распространение COVID-19 в различных странах мира и Российской Федерации, дана оценка их эффективности.

The review analyses the information on the epidemiological situation on COVID-19 around the world. Presented is the assessment of the major epidemiological parameters (basic reproductive rate, lethality, incubation period, and serial interval). Demonstrated is the share of severe cases among different age groups and the general structure of incidence by the severity of clinical course. The paper provides the classification of response models internationally depending upon the complex of measures undertaken at different stages of epidemic process. Reviewed are the key response actions to control the COVID-19 transmission in different countries of the world and the Russian Federation and given is the assessment of their effectiveness.

COVID-19пандемияэпидемиологические особенностинациональное реагированиеCOVID-19pandemicepidemiological featuresnational responseReferencesWHO Director-General’s opening remarks at the media briefing on COVID-19 – 3 March 2020. World Health Organization, March 3, 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---3-march-2020.WHO Director-General’s opening remarks at the media briefing on COVID-19 – 3 March 2020. World Health Organization, March 3, 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---3-march-2020.Virtual press conference on COVID-19. 11 March 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emer-gencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2.Virtual press conference on COVID-19. 11 March 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emer-gencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2.Novel Coronavirus – China. Disease outbreak news: Update 12 January 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronaviruschina/en/.Novel Coronavirus – China. Disease outbreak news: Update 12 January 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronaviruschina/en/.Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, XiaoyingGu, Zhenshun Cheng, Ting Yu, Jiaan Xia, Yuan Wei, Wenjuan Wu, XueleiXie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, JungangXie, Guangfa Wang, Rongmeng Jiang, Zhancheng Gao, Qi Jin, Jianwei Wang, Bin Cao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, XiaoyingGu, Zhenshun Cheng, Ting Yu, Jiaan Xia, Yuan Wei, Wenjuan Wu, XueleiXie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, JungangXie, Guangfa Wang, Rongmeng Jiang, Zhancheng Gao, Qi Jin, Jianwei Wang, Bin Cao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Liu, Yuan Wei, Jia’an Xia, Ting Yu, Xinxin Zhang, Li Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395(10223):507–13. DOI: 10.1016/S0140-6736(20)30211-7.Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Liu, Yuan Wei, Jia’an Xia, Ting Yu, Xinxin Zhang, Li Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395(10223):507–13. DOI: 10.1016/S0140-6736(20)30211-7.Roujian Lu, Xiang Zhao, Juan Li, PeihuaNiu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu, Yuhai Bi, Xuejun Ma, Faxian Zhan, Liang Wang, Tao Hu, Hong Zhou, Zhenhong Hu, Weimin Zhou, Li Zhao, Jing Chen, Yao Meng, Ji Wang, Yang Lin, Jianying Yuan, ZhihaoXie, Jinmin Ma, William J Liu, Dayan Wang, Wenbo Xu, Edward C Holmes, George F Gao, Guizhen Wu, Weijun Chen, Weifeng Shi, Wenjie Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020; 395(10224):565–74. DOI: 10.1016/S0140-6736(20)30251-8.Roujian Lu, Xiang Zhao, Juan Li, PeihuaNiu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu, Yuhai Bi, Xuejun Ma, Faxian Zhan, Liang Wang, Tao Hu, Hong Zhou, Zhenhong Hu, Weimin Zhou, Li Zhao, Jing Chen, Yao Meng, Ji Wang, Yang Lin, Jianying Yuan, ZhihaoXie, Jinmin Ma, William J Liu, Dayan Wang, Wenbo Xu, Edward C Holmes, George F Gao, Guizhen Wu, Weijun Chen, Weifeng Shi, Wenjie Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020; 395(10224):565–74. DOI: 10.1016/S0140-6736(20)30251-8.Ji W., Wang W., Zhao X., Zai J., Li X. Cross-species trans- mission of the newly identified coronavirus 2019-nCoV. J. Med. Virol. 2020; 92(4):433–40. DOI: 10.1002/jmv.25682.Ji W., Wang W., Zhao X., Zai J., Li X. Cross-species trans- mission of the newly identified coronavirus 2019-nCoV. J. Med. Virol. 2020; 92(4):433–40. DOI: 10.1002/jmv.25682.World Health Organization. Infection prevention and control during health care for probable or confirmed cases of coronavirus (COVID-19) infection: interim guidance. (Cited 27 Mar 2020). [Internet]. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novelcoronavirus-(ncov)-infection-is-suspected-20200125.World Health Organization. Infection prevention and control during health care for probable or confirmed cases of coronavirus (COVID-19) infection: interim guidance. (Cited 27 Mar 2020). [Internet]. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novelcoronavirus-(ncov)-infection-is-suspected-20200125.Sheng Zhang, Meng Yuan Diao, Wenbo Yu, Lei Pei, Zhaofen Lin, Dechang Chen. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruize ship: A data-driven analysis. Int. J. Infect. Dis. 2020; 93:201–4. DOI: 10.1016/j.ijid.2020.02.033Sheng Zhang, Meng Yuan Diao, Wenbo Yu, Lei Pei, Zhaofen Lin, Dechang Chen. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruize ship: A data-driven analysis. Int. J. Infect. Dis. 2020; 93:201–4. DOI: 10.1016/j.ijid.2020.02.033Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). World Health Organization, Feb. 28, 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). World Health Organization, Feb. 28, 2020 (cited 1 Apr 2020). [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.Ghani A.C., Donnelly C.A., Cox D.R., Griffin J.T., Fraser C., Lam T.H., Ho L.M., Chan W.S., Anderson R.M., Hedley A.J., Leung G.M. Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease. Am. J. Epidemiol. 2005; 162(5):479–86. DOI: 10.1093/aje/kwi230.Ghani A.C., Donnelly C.A., Cox D.R., Griffin J.T., Fraser C., Lam T.H., Ho L.M., Chan W.S., Anderson R.M., Hedley A.J., Leung G.M. Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease. Am. J. Epidemiol. 2005; 162(5):479–86. DOI: 10.1093/aje/kwi230.The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020. China CDC Weekly. 2020, 2(8):113–22.The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020. China CDC Weekly. 2020, 2(8):113–22.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. DOI: 10.1001/jama.2020.1585.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. DOI: 10.1001/jama.2020.1585.Kampf G., Todt D., Pfaender S., Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection. 2020; 104(3):246–51. DOI: 10.1016/j.jhin.2020.01.022.Kampf G., Todt D., Pfaender S., Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection. 2020; 104(3):246–51. DOI: 10.1016/j.jhin.2020.01.022.Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R. Meredith, Andrew S. Azman, Nicholas G. Reich, Justin Lessler. The incubation period of corona- virus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 2020 Mar 10. DOI: 10.7326/M20-0504.Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R. Meredith, Andrew S. Azman, Nicholas G. Reich, Justin Lessler. The incubation period of corona- virus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 2020 Mar 10. DOI: 10.7326/M20-0504.Bai Y., Yao L., Wei T., Tian F., Jin D.Y., Chen L., Wang M. Presumed asymptomatic carrier transmission of COVID-19. JAMA. Published online February 21, 2020. DOI: 10.1001/jama.2020.2565.Bai Y., Yao L., Wei T., Tian F., Jin D.Y., Chen L., Wang M. Presumed asymptomatic carrier transmission of COVID-19. JAMA. Published online February 21, 2020. DOI: 10.1001/jama.2020.2565.World Health Organization. Critical preparedness, readiness and response actions for COVID-19: interim guidance. 22 March 2020 (cited 27 Mar 2020). [Internet]. Available from: https:// www.who.int/publications-detail/critical-preparedness-readinessand-response-actions-for-covid-19.World Health Organization. Critical preparedness, readiness and response actions for COVID-19: interim guidance. 22 March 2020 (cited 27 Mar 2020). [Internet]. Available from: https:// www.who.int/publications-detail/critical-preparedness-readinessand-response-actions-for-covid-19.Anderson R.M., Heesterbeek H., Klinkenberg D., Hollingsworth T.D. How will country-based mitigation measures influence the course of the COVID-19 epidemic? The Lancet. 395(10228):931–4. DOI: 10.1016/S0140-6736(20)30567-5.Anderson R.M., Heesterbeek H., Klinkenberg D., Hollingsworth T.D. How will country-based mitigation measures influence the course of the COVID-19 epidemic? The Lancet. 395(10228):931–4. DOI: 10.1016/S0140-6736(20)30567-5.Qualls N., Levitt A, Kanade N., Wright-Jegede N., Dopson S., Biggerstaff M., Reed C., UzicaninA. (21 April 2017). Community Mitigation Guidelines to Prevent Pandemic Influenza – United States, 2017. MMWR. Recommendations and Reports. 66(1):1–34. doi:10.15585/mmwr.rr6601a1.PMC5837128. PMID 28426646Qualls N., Levitt A, Kanade N., Wright-Jegede N., Dopson S., Biggerstaff M., Reed C., UzicaninA. (21 April 2017). Community Mitigation Guidelines to Prevent Pandemic Influenza – United States, 2017. MMWR. Recommendations and Reports. 66(1):1–34. doi:10.15585/mmwr.rr6601a1.PMC5837128. PMID 28426646Hatchett R.J., Carter E. Mecher C.E., Lipsitch M. Public health interventions and epidemic intensity during the 1918 in- fluenza pandemic. PNAS. 2007; 104(18)7582–7. DOI: 10.1073/pnas.0610941104.Hatchett R.J., Carter E. Mecher C.E., Lipsitch M. Public health interventions and epidemic intensity during the 1918 in- fluenza pandemic. PNAS. 2007; 104(18)7582–7. DOI: 10.1073/pnas.0610941104.

The authors declare that there are no conflicts of interest present.